Edwards Lifesciences Corporation (NYSE:EW) Stock Rated “Moderate Buy” by Wall Street Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has been given an average recommendation of “Moderate Buy” by the twenty-six research firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $100.31.

Several research analysts recently issued reports on the stock. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $104.00 target price on shares of Edwards Lifesciences in a report on Tuesday. BTIG Research reiterated a “buy” rating and issued a $110.00 target price on shares of Edwards Lifesciences in a research note on Friday, September 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Thursday, October 15th. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $87.00 to $101.00 in a research report on Friday, July 24th.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 5,045 shares of company stock worth $451,596. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of the business. Flagship Harbor Advisors LLC increased its position in shares of Edwards Lifesciences by 1.2% in the third quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock valued at $916,000 after buying an additional 125 shares in the last quarter. Fifth Third Wealth Advisors LLC lifted its position in shares of Edwards Lifesciences by 1.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock valued at $627,000 after buying an additional 132 shares in the last quarter. Signaturefd LLC lifted its position in shares of Edwards Lifesciences by 1.4% during the 3rd quarter. Signaturefd LLC now owns 10,034 shares of the medical research company’s stock valued at $866,000 after buying an additional 142 shares in the last quarter. NorthRock Partners LLC lifted its position in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after buying an additional 153 shares in the last quarter. Finally, Elevation Wealth Partners LLC lifted its position in shares of Edwards Lifesciences by 24.8% during the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock valued at $67,000 after buying an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $90.78 on Wednesday. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $96.29. The business has a 50-day moving average price of $88.06 and a 200-day moving average price of $85.30.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.